if his name appeared in the dictionary, beside it, I would scowl with rolling eyes upon:1- egotistical, and in poor taste, 2- with lack of everything promised, and a fool for a friend 3- cares nothing of time or place, too far away within himself. Well, I suppose I would be the author of that book.
Definiens invites you to attend The International Symposium for Tissue Phenomics, happening April 26-27, 2016 in Cambridge, Massachusetts. Enjoy expert presentations on immuno-oncology and big data, valuable panel discussions, all while networking with your peers and other industry experts.
Hear speakers from cutting edge organizations such as:
Join us for our November 11 webinar!
Dr. Nathalie Harder will be presenting the Tissue Phenomics® methodology to discover new tissue-based diagnostics using image and clinical data and known clinical outcome for the benefit of individual patients.
You can select from one of two different broadcast times to watch this webinar.
Join us for our September 23 webinar on Applying Tissue Phenomics® to Clinical Questions for Patient Stratification. Dr. Peter Caie will be presenting how Tissue Phenomics can be utilized to identify previously undiscovered prognostic and predictive image-based features or combinations of features for patient stratification.
For your convenience, select from one of two different broadcast times…
Definiens Strengthens Tissue Phenomics Research with microDimensions’ Technology
microDimensions, global provider of state-of-the-art digital pathology software and services, won Definiens as one of their customers. Definiens is the pioneer in Tissue Phenomics® solutions for diagnostics development and commercialization and was recently acquired by MedImmune, the biologics research and development arm of AstraZeneca.
As a new customer of microDimensions, Definiens will be…
Phenomics, the use of unique tissue signatures correlated to genetic
or patient outcome data to develop precise and powerful tissue-based
diagnostics, continues to be a key driver in the growth of personalized
medicine in oncology. This year’s Symposium will focus on new
advancements and important work being done in the space, specifically
“The Future of Cancer Dx,” as well tissue-based immunoprofiling, big
data and data integration, and digital pathology and diagnostics in
The symposium will feature presentations and discussions by leading
distinguished researchers and speakers, including:
Joseph Beecham, Nanostring Technologies, Inc.
Carlo Bifulco, Providence Health & Services, Inc.
Gerd Binnig, Definiens AG
Peter Caie, University of St. Andrews
Manfred Dietel (Chair), Charité
Belma Dogdas, Merck & Co., Inc.
Bernhard Fox (Chair), Providence Health & Services, Inc.
Jerôme Galon, Inserm
James Gulley, NIH
Michael Hehenberger, IBM
Ron Herbst, MedImmune
Jeff Hodgin, University of Michigan Medical School
Dirk Jäger, NCT Heidelberg
Trevor McKee, Princess Margaret Cancer Centre
Holger Moch, University of Zurich
Bob Silverman, Gilde Healthcare
“The annual Symposium has become a central meeting for discussion on
cancer companion diagnostics and personalized medicine,” said Thomas
Heydler, CEO, Definiens. “Significant advancements are being made with
Tissue Phenomics, and this event, which brings together some of the
greatest minds in the industry, is critical to continuing the dialogue,
collaboration and education needed for the progress of tissue-based
diagnostics and immune-oncology.”
The symposium will take place from April 26-27, 2016 at the Hotel
Marlowe in Cambridge, Massachusetts. Register online at http://www.cvent.com/d/sfqk2w.
For more information, please contact Lina Willis, global marketing and
conference manager at email@example.com.
Definiens is the pioneering provider of Tissue Phenomics® solutions for
biomarker and companion diagnostics development. Definiens’ technology
empowers smarter tissue-based diagnostics by leveraging quantitative
tissue readouts and other big data sources. By enabling the development
of powerful and precise assays for patient stratification and clinical
trial enrollment, Definiens aims to dramatically improve patient
outcomes. Definiens’ Tissue Phenomics approach was awarded the 2013
Frost and Sullivan Company of the Year Award for Global Tissue
Diagnostics and Pathology Imaging. For more information, please visit: www.definiens.com.